Merck & Co., Inc. (MRK) vs Vanguard S&P 500 ETF (VOO)

Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.

Vanguard S&P 500 ETF is an exchange-traded fund that gives investors diversified exposure to large-cap U.S. companies in the S&P 500 Index. It is designed to track or represent a basket of publicly traded securities rather than a single company, making it useful for portfolio allocation, regional exposure, and thematic positioning. Its performance depends on the underlying holdings, sector and country weights, currency movements where relevant, fund expenses, and broader equity-market conditions.